Please Wait.....
Report
Induced Pluripotent Stem Cells: Global Markets
Market Research Report I 2024-11-07 I 152 Pages I BCC Research
Description
Report Scope
The scope of this study encompasses an investigation of the market. BCC Research analyzes this market based on application type, product function, generation of iPSC and types of iPSC derived cells and species. Application-based market segments include drug development and toxicity testing, academic research and regenerative medicine. Product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation and cell analysis. iPSC-derived cell-type-based market segments include hepatocytes, neurons, cardiomyocytes, endothelial cells and other cell types. Other cell types include astrocytes, fibroblasts and hematopoietic progenitor cells. BCC Research determines the current market status in each segment, examines its impact on future needs and presents growth forecasts through 2028.
The report also provides a detailed analysis of the market's drivers, restraints, challenges and opportunities. In addition, the report includes the company profiles of the key players with detailed information about their business segments, financials, product portfolios and recent developments. it also provides detailed information on this market, emerging technologies and new developments, regulatory landscape, patent analysis, pipeline analysis and investment outlook and deals.
Report Includes
- 28 data tables and 56 additional tables
- An analysis of the global market for induced pluripotent stem cells (iPSCs) or artificial stem cells
- Analyses of global market trends, with market revenue data from 2020 to 2023, and projected CAGRs through 2028
- Estimate of the size and revenue prospects of the global market, along with a market share analysis by reprogramming method, generation method, application, product function, iPSC-derived cell type, species, end use, and region
- Facts and figures pertaining to the market dynamics, technological advances, regulations, and the macroeconomic factors that influence the industry
- A Porter's Five Forces model, as well as global supply chain and PESTLE analyses
- Insights into iPSC research activity, emerging technologies, clinical trials and pipeline products
- Patent activity and analysis of recent patent grants/publications
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, ESG score analysis, and the ESG practices of leading companies
- Analysis of the industry structure, including company market shares, strategic alliances, M&A activity and a venture funding outlook
- Profiles of market leaders, including Fujifilm Cellular Dynamics (FCDI) Inc., Axol Bioscience Ltd., Merck KGaA, Thermo Fisher Scientific Inc., and Takara Bio Inc.
Executive Summary
Summary:
Induced pluripotent stem cells (iPSCs) are artificial stem cells generated from somatic cells through the simultaneous expression of specific factors associated with pluripotency. The discovery of human iPSCs (hiPSCs) and their capacity to differentiate into various cell types of the body has led to significant scientific interest and enthusiasm. In contrast to embryonic stem cells, iPSCs offer an added advantage of being easily derived from human samples without any ethical concerns.
The rapid evolution of human iPSC technology since 2007 led to an exciting new age for the fields of disease modeling, drug discovery, stem cell biology and regenerative medicine. Human iPSCs were rapidly applied to create human "disease-in-a-dish" models and for drug screening to check for potential toxicities as well as efficacy shortly after the technology was developed. With the rise in interest in phenotypic screening and the benefits of using human iPSCs for disease modeling over conventional cellular screens, these methods are currently gaining traction. These benefits include their human origin, ease of use, expandability, capacity to generate nearly any type of cell wanted, avoidance of the moral dilemmas surrounding human embryonic stem cells (ESCs) and the possibility of employing patientspecific iPSCs to create personalized therapeutics. The creation of genetically specified human iPSCbased disease models is becoming easier with current developments in gene-editing tools, particularly CRISPR/Cas9. Additionally, iPSCs play a significant role in a new generation of cellular platforms that are more physiologically similar and have several cell types and three-dimensional (3D) designs.
However, there are certain challenges associated with the use of iPSCs, including issues with clonal selection, in vitro culture, adaptability, and/or cell multiplication. Thus, even though the field of iPSCs has come a long way, there are still many issues that need to be seriously addressed to transform hope to reality regarding the effective clinical application of these cells in regenerative medicine.
The iPSC market was valued at $3.1 billion in 2022 and is forecasted to grow at a CAGR of 9.1% to reach a value of $5.2 billion by end of 2028.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Introduction
Induced Pluripotent Stem Cells (iPSC) Generation
Chapter 3 Market Dynamics
Global Market Dynamics
Market Drivers
Increasing Prevalence of Chronic Diseases
Increasing Investment in Biotechnology Industry
Increasing Demand for Personalized Medicines
Increasing Investments for Drug Research and Development
Demand for Effective Drug Discovery and Development Process
Minimizing Animal Testing
Market Restraints
High Development Costs and Lack of Skilled Workforce
Challenges Associated with iPSC-based Disease Modeling, Cell Therapy and Drug Discovery
Market Opportunities
Technological Advances
Growth in iPSC Banking
Chapter 4 Emerging Technologies and Developments
Advances in the iPSC Research
Reprogramming Technologies
Gene Editing Technologies
3D Organoids
Regenerative Medicine
Evolution and Current Application of Artificial Intelligence (AI) in iPSC Research
Chapter 5 Clinical Trial Analysis
Clinical Trials
Chapter 6 Patent Analysis
Patent Analysis
Chapter 7 Market Segmentation Analysis
Segmentation Breakdown
Overview
Generation of Induced Pluripotent Stem Cells -- Market Analysis, by Reprogramming Method
Market for Induced Pluripotent Stem Cells, by Generation Method
Market for Induced Pluripotent Stem Cells, by Application
Academic Research
Pharmaco-toxicological Screening
Drug Discovery and Development
Disease Modeling
Tissue Engineering
Cell Therapy
Global Market
Regional Markets for iPSCs, by Application
iPSC-derived Tissue Cell Market, by Type
Cardiomyocytes
Neurons
Endothelial Cells
Hepatocytes
Other Cells
iPSC-derived Tissue Cell Market, by Species
Global Market
iPSC-derived Tissue Cell Market, by Application
Global Market
Market for Induced Pluripotent Stem Cells, by Product Function
Global Market
Regional Markets for iPSCs, by Product Function
Market for Induced Pluripotent Stem Cells, by End Use
Induced Pluripotent Stem Cell Contract Service Types
Major Players
Global Market
Geographic Breakdown
Market for Induced Pluripotent Stem Cells, by Region
The U.S.
Europe
Asia-Pacific
Rest of the World
Chapter 8 Competitive Intelligence
Competitive Landscape -- Overview
Strategic Analysis
Agreements
Collaborations & Strategic Alliances
Partnerships
New Product Development and Launches
Expansions and Acquisitions
Fund Raising
Approval and Clinical Trials
Others
Major Companies in Induced Pluripotent Stem Cells Market, by Type of Offerings
Chapter 9 Appendix
Methodology
Abbreviations
Sources
Company Profiles
ATCC
AXOL BIOSCIENCE LTD.
BIO-TECHNE
FUJIFILM CELLULAR DYNAMICS INC.
LONZA
MERCK KGAA
NCARDIA
QIAGEN
REPROCELL INC.
STEMCELL TECHNOLOGIES
TAKARA BIO INC.
THERMO FISHER SCIENTIFIC INC.
List of Tables
Summary Table : Global Market for Induced Pluripotent Stem Cells, by Reprogramming Method, Through 2028
Table 1 : Projected Number of Adults 50 Years and Older with ?1 Chronic Condition in the United States, 2020-2050
Table 2 : The U.S. NIH Funding for Various Disease Conditions, 2019-2025
Table 3 : Brief Information on iPSC Repositories
Table 4 : Induced Pluripotent Stem Cells Pipeline, 2023
Table 5 : List of Selected Patents Published on iPSC Technology, 2021
Table 6 : List of Selected Patents Published on iPSC Technology, 2022
Table 7 : List of Selected Patents Published on iPSC Technology, 2023
Table 8 : List of Selected Patents Published on iPSC Technology, Till August 2024
Table 9 : Summary of Different Reprogramming Methods
Table 10 : Global Market for the Generation of Induced Pluripotent Stem Cells, by Reprogramming Method, Through 2028
Table 11 : Global Market for Induced Pluripotent Stem Cells, by Method, Through 2028
Table 12 : Selected Interventional Clinical Trials of iPSC-based Cell Therapy
Table 13 : Global Market for Induced Pluripotent Stem Cells, by Application, Through 2028
Table 14 : The U.S. Market for Induced Pluripotent Stem Cells, by Application, Through 2028
Table 15 : European Market for Induced Pluripotent Stem Cells, by Application, Through 2028
Table 16 : Asia-Pacific Market for Induced Pluripotent Stem Cells, by Application, Through 2028
Table 17 : RoW Market for Induced Pluripotent Stem Cells, by Application, Through 2028
Table 18 : Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Type, Through 2028
Table 19 : Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Species, Through 2028
Table 20 : Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Application, Through 2028
Table 21 : Global Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
Table 22 : The U.S. Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
Table 23 : European Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
Table 24 : Asia-Pacific Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
Table 25 : RoW Market for Induced Pluripotent Stem Cells, by Product Function, Through 2028
Table 26 : Global Market for Induced Pluripotent Stem Cells, by End Use, Through 2028
Table 27 : Major Companies Providing iPSC Contract Services, by State/Country
Table 28 : Global Market for Induced Pluripotent Stem Cell Contract Services, by Region, Through 2028
Table 29 : Global Market for Induced Pluripotent Stem Cells, by Region, Through 2028
Table 30 : The U.S. Market for Induced Pluripotent Stem Cells, by State, Through 2028
Table 31 : European Market for Induced Pluripotent Stem Cells, by Country, Through 2028
Table 32 : Asia-Pacific Market for Induced Pluripotent Stem Cells, by Country, Through 2028
Table 33 : Agreements: Induced Pluripotent Stem Cells Market, 2019-2024
Table 34 : Collaborations and Strategic Alliances: Induced Pluripotent Stem Cells Market, 2019-2024
Table 35 : Partnerships: Induced Pluripotent Stem Cells Market, 2020-2023
Table 36 : New Product Development and Launches: Induced Pluripotent Stem Cells Market, 2020-2023
Table 37 : Expansions and Acquisitions: Induced Pluripotent Stem Cells Market, 2020-2023
Table 38 : Fund Raising: Induced Pluripotent Stem Cells Market, 2020-2024
Table 39 : Approvals and Clinical Trials: Induced Pluripotent Stem Cells Market, 2020-2024
Table 40 : Other Competitive Strategies: Induced Pluripotent Stem Cells Market, 2020-2024
Table 41 : Major Companies in the Induced Pluripotent Stem Cells Market
Table 42 : Glossary of Terms Used in This Report
Table 43 : Report Information Sources
Table 44 : ATCC: Company Snapshot
Table 45 : ATCC: Product Portfolio
Table 46 : ATCC: News/Key Developments, 2023 and 2024
Table 47 : Axol Bioscience Ltd.: Company Snapshot
Table 48 : Axol Bioscience Ltd.: Product Portfolio
Table 49 : Axol Bioscience Ltd.: News/Key Developments, 2021-2024
Table 50 : Bio-Techne: Company Snapshot
Table 51 : Bio-Techne: Financial Performance, FY 2022 and 2023
Table 52 : Bio-Techne: Product Portfolio
Table 53 : Bio-Techne: News/Key Developments, 2021-2023
Table 54 : Fujifilm Cellular Dynamics Inc.: Company Snapshot
Table 55 : Fujifilm Cellular Dynamics Inc.: Product Portfolio
Table 56 : Fujifilm Cellular Dynamics Inc.: News/Key Developments, 2021-2023
Table 57 : Lonza: Company Snapshot
Table 58 : Lonza: Financial Performance, FY 2022 and 2023
Table 59 : Lonza: Product Portfolio
Table 60 : Lonza: News/Key Developments, 2020
Table 61 : Merck KGaA: Company Snapshot
Table 62 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 63 : Merck KGaA.: Product Portfolio
Table 64 : Merck KGaA: News/Key Developments, 2021-2024
Table 65 : Ncardia: Company Snapshot
Table 66 : Ncardia: Product Portfolio
Table 67 : Ncardia: News/Key Developments, 2021-2024
Table 68 : Qiagen: Company Snapshot
Table 69 : Qiagen: Financial Performance, FY 2022 and 2023
Table 70 : Qiagen: Product Portfolio
Table 71 : REPROCELL Inc.: Company Snapshot
Table 72 : REPROCELL Inc.: Product Portfolio
Table 73 : REPROCELL Inc.: News/Key Developments, 2021-2024
Table 74 : STEMCELL Technologies.: Company Snapshot
Table 75 : STEMCELL Technologies: Product Portfolio
Table 76 : STEMCELL Technologies: News/Key Developments, 2021-2022
Table 77 : Takara Bio Inc.: Company Snapshot
Table 78 : Takara Bio Inc.: Financial Performance, FY 2022 and 2023
Table 79 : Taraka Bio Inc.: Product Portfolio
Table 80 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 81 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 82 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 83 : Thermo Fisher Scientific Inc.: News/Key Developments, 2023 and 2024
List of Figures
Summary Figure : Global Market for Induced Pluripotent Stem Cells, by Reprogramming Method, 2020-2028
Figure 1 : Methodology for the Generation of Induced Pluripotent Stem Cells
Figure 2 : Snapshot of the Market Dynamics for iPSCs
Figure 3 : Venture Averages for Biopharma Therapeutics and Platform Companies, 2010-2024
Figure 4 : Personalized Medicines Contribution in Total FDA Approvals, 2015-2023
Figure 5 : Global Pharmaceutical R&D Spending, by Select Country/Region, 2010-2022
Figure 6 : Phases of the Pharmaceutical Industry Research and Development Process
Figure 7 : iPSC-derived Organoids Used for Drug Screening
Figure 8 : Temporal Distribution of Studies Using ESCs, iPSCs, Somatic Cell Nuclear Transfer (SCNT) Cells and Parthenotic PSCs (pPSCs), Jan 1, 2011-Dec 13, 2022
Figure 9 : Clinical-trial Analysis: Induced Pluripotent Stem Cells, as of August 2024
Figure 10 : Number of Patents Documented Over Time on iPSC Technology, 2010-2024
Figure 11 : Number of Granted Patents Documents on iPSC Technology, by Country, 2021-2024
Figure 12 : PubMed Citations and Human iPSC Lines Registered in hPSCreg and EBiSC, 2007-2022
Figure 13 : Published Applications of hiPSC Technology from Top 20 Pharma Companies, 2010-2020
Figure 14 : Global Market for the Generation of Induced Pluripotent Stem Cells, by Reprogramming Method, 2020-2028
Figure 15 : Global Market Shares of Induced Pluripotent Stem Cells, by Reprogramming Method, 2022
Figure 16 : Global Market for Induced Pluripotent Stem Cells, by Method, 2020-2028
Figure 17 : Global Market Shares of Induced Pluripotent Stem Cells, by Method, 2022
Figure 18 : Utility of hiPSCs to Humanize Drug Discovery
Figure 19 : Autologous and Allogeneic iPSC-Based Cell Therapy
Figure 20 : Global Market for Induced Pluripotent Stem Cells, by Application, 2020-2028
Figure 21 : Global Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
Figure 22 : The U.S. Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
Figure 23 : European Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
Figure 24 : Asia-Pacific Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
Figure 25 : RoW Market Shares of Induced Pluripotent Stem Cells, by Application, 2022
Figure 26 : Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Type, 2020-2028
Figure 27 : Global Market Shares of Induced Pluripotent Stem Cell-derived Tissue Cells, by Type, 2022
Figure 28 : Global Market for Induced Pluripotent Stem Cell-derived Tissue Cells, by Species, 2020-2028
Figure 29 : Global Market Shares of Induced Pluripotent Stem Cell-derived Tissue Cells, by Application, 2022
Figure 30 : Global Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
Figure 31 : The U.S. Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
Figure 32 : European Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
Figure 33 : Asia-Pacific Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
Figure 34 : RoW Market Shares of Induced Pluripotent Stem Cells, by Product Function, 2022
Figure 35 : Global Market Shares of Induced Pluripotent Stem Cells, by End Use, 2022
Figure 36 : Global Market Shares of Induced Pluripotent Stem Cell Contract Services, by Region, 2022
Figure 37 : Global Market Shares of Induced Pluripotent Stem Cells, by Region, 2022
Figure 38 : NIH Spending on Induced Pluripotent Stem Cell Research in the U.S., 2015-2023
Figure 39 : The U.S. Market Shares of Induced Pluripotent Stem Cells, by State, 2022
Figure 40 : European Market Shares of Induced Pluripotent Stem Cells, by Country, 2028
Figure 41 : Asia-Pacific Market Shares of Induced Pluripotent Stem Cells, by Country, 2022
Figure 42 : Global Market Shares of Induced Pluripotent Stem Cells, by Key Strategies Adopted, 2019-2024
Figure 43 : Bio-Techne: Revenue Share, by Business Unit, FY 2023
Figure 44 : Bio-Techne: Revenue Share, by Country/Region, FY 2023
Figure 45 : Lonza: Revenue Share, by Business Unit, FY 2023
Figure 46 : Lonza: Revenue Share, by Country/Region, FY 2023
Figure 47 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 48 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 49 : Qiagen: Revenue Share, by Business Unit, FY 2023
Figure 50 : Qiagen: Revenue Share, by Country/Region, FY 2023
Figure 51 : Takara Bio Inc.: Revenue Share, by Business Unit, FY 2023
Figure 52 : Takara Bio Inc.: Revenue Share, by Country/Region, FY 2023
Figure 53 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 54 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security